Familial Mediterranean fever (FMF) is an autosomal recessive autoinflammatory disease of childhood and adulthood. Development of systemic amyloidosis and frequent attack influence quality of life and survival. There is sporadic evidence indicating subclinical inflammation in patients with FMF. We aimed to assess subclinical inflammation using neutrophil to lymphocyte ratio (NLR), platelet to lymphocyte ratio (PLR), and C-reactive protein (CRP) in pediatric patients with FMF in the attack-free period. In this retrospective study, we reviewed the files of all FMF patients in our pediatric rheumatology outpatient clinic in a tertiary center and enrolled those with sufficient clinical and laboratory data. We also enrolled 73 controls. We grouped the patients according to being in attack period or attack-free period. We compared CRP, NLR, PLR, and WBC (white blood cell) levels between different mutations and polymorphisms. We also compared patients in the attack period with those in attack-free period. We enrolled 61 patients in attack period, 509 patients in attack-free period, and 73 controls. There was no difference between patients with different mutations with respect to NLR or PLR levels in the attack-free period. However, CRP levels were higher in patients with homozygous exon 10 mutations, especially those with homozygous M694V mutations compared with other mutations. However, CRP levels were mostly normal in these patients. Our data are against the reported fact that patients with FMF have higher NLR or PLR levels in attack-free periods. However, CRP levels were higher in the presence of homozygous exon 10 mutations (in particular homozygous M694V mutations).

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10067-016-3275-0DOI Listing

Publication Analysis

Top Keywords

attack-free period
20
subclinical inflammation
12
patients
12
patients fmf
12
patients attack
12
attack period
12
nlr plr
12
crp levels
12
familial mediterranean
8
mediterranean fever
8

Similar Publications

Background: Chronic cluster headache (CCH) is an excruciatingly painful condition that can be difficult to treat sufficiently with the available medical treatment options. The greater occipital nerves (GON) are of major interest in treating CCH, and various invasive treatment modalities, such as stimulating or blocking the nerves, have been applied. Because the terminal segment of the GON has a superficial course, the nerve is also accessible for non-invasive transcutaneous stimulation.

View Article and Find Full Text PDF

Background: Neuromyelitis optica spectrum disorder (NMOSD), a central nervous system inflammatory disease associated with aquaporin-4 immunoglobulin G (AQP4-IgG), is conventionally treated with oral steroids and immunosuppressants (IS) in Japan. Several biologics which show great efficacy in the clinical trials have been developed recently. However, studies on their efficacy, especially those comparing them with conventional treatments in real-world situations are lacking.

View Article and Find Full Text PDF

CRISPR-Based Therapy for Hereditary Angioedema.

N Engl J Med

October 2024

From Amsterdam Cardiovascular Sciences, Amsterdam University Medical Center, University of Amsterdam, Amsterdam (D.M.C., R.S.P); Cambridge University Hospitals, NHS Foundation Trust, Cambridge, United Kingdom (P.G.); the Institute of Allergology, Charité-Universitätsmedizin Berlin, Freie Universität Berlin and Humboldt-Universität zu Berlin, and Immunology and Allergology, Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Berlin (M.M.), and the Department of Children and Adolescents, University Hospital Frankfurt, Goethe University Frankfurt, Frankfurt (E.A.-P.) - all in Germany; the Department of Medicine, Campbelltown Hospital and Western Sydney University, Sydney (C.H.K.); University of Lille, U1286-INFINITE-Institute for Translational Research in Inflammation, F-59000, INSERM, and the Department of Internal Medicine and Clinical Immunology, CHU Lille, National Reference Center for Angioedema (CREAK), Lille (D.L.), and CREAK, Angioedema Center of Reference and Excellence (ACARE), Grenoble Alpes University Hospital, and the Translational Research in Autoimmunity and Inflammation Arm (T-RAIG), French National Center for Scientific Research (CNRS), Grenoble (L.B.) - all in France; Intellia Therapeutics, Cambridge, MA (D.M., J.S.B., M.Y.S., A.G., Y.X., A.M.A., D.L.); and the Department of Immunology, Auckland City Hospital, and the Department of Medicine, University of Auckland - both in Auckland, New Zealand (K.L., H.J.L.).

Background: Hereditary angioedema is a rare genetic disease characterized by severe and unpredictable swelling attacks. NTLA-2002 is an in vivo gene-editing therapy that is based on clustered regularly interspaced short palindromic repeats (CRISPR)-CRISPR-associated protein 9. NTLA-2002 targets the gene encoding kallikrein B1 ().

View Article and Find Full Text PDF
Article Synopsis
  • Cardiovascular diseases are the leading cause of death in patients with hereditary angioedema due to C1-inhibitor deficiency (HAE-C1INH), often exacerbated by long-term treatments like attenuated androgens that can increase cardiovascular risk.
  • A case study of a 56-year-old HAE-C1INH patient with numerous health issues, including kidney impairment and hypertension, showcased a successful transition from traditional androgen therapy to the modern treatment, lanadelumab, starting in 2020.
  • After beginning lanadelumab, the patient saw no angioedema attacks, experienced a decrease in cardiovascular risk factors like cholesterol and body mass index, and improved overall health outcomes, indicating this treatment's effectiveness and safety.
View Article and Find Full Text PDF
Article Synopsis
  • Hereditary angioedema (HAE) is a chronic disease requiring effective long-term preventive treatments, prompting a study to evaluate the safety and efficacy of garadacimab, a new medication for HAE.
  • In an interim analysis of the ongoing phase 3 VANGUARD study, involving 161 patients, most treatment-emergent adverse events (TEAEs) were mild, with injection-site reactions being the most common, and no serious complications linked to garadacimab were reported.
  • The results showed a significant reduction in HAE attacks, with 60% of patients remaining attack-free, indicating that garadacimab offers a safe and effective long-term treatment option for patients with
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!